InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 16.10
-0.10 (-0.62%)
Jan 22, 2026, 2:02 PM CST
InnoPharmax Revenue
InnoPharmax had revenue of 46.64M TWD in the half year ending June 30, 2025, with 34.61% growth. This brings the company's revenue in the last twelve months to 55.77M, up 61.25% year-over-year. In the year 2024, InnoPharmax had annual revenue of 32.30M, down -29.90%.
Revenue (ttm)
55.77M
Revenue Growth
+61.25%
P/S Ratio
31.25
Revenue / Employee
1.69M
Employees
33
Market Cap
1.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.30M | -13.78M | -29.90% |
| Dec 31, 2023 | 46.07M | 16.94M | 58.15% |
| Dec 31, 2022 | 29.13M | -18.93M | -39.38% |
| Dec 31, 2021 | 48.06M | -88.82M | -64.89% |
| Dec 31, 2020 | 136.88M | 51.99M | 61.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |